Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on December 16, 2022, covering events occurring on December 19, 2022. The company is incorporated in Florida and its common stock trades on the NYSE American under the symbol OGEN.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses specific activity related to the company's At-the-Market (ATM) Sales Program:
- Shares Sold (Q4 2022): 357,438 shares of common stock.
- Average Sale Price: $0.2024 per share.
- Termination Penalties: None.
Material Changes
The filing reports two material changes:
- Termination of Sales Agreement: The Company terminated its Sales Agreement with A.G.P./Alliance Global Partners (AGP) regarding the ATM Program. The termination became effective on December 29, 2022, halting further stock sales through this program.
- Board of Directors Change: Mr. Charles Pope was elected as the new Chairman of the Board. Dr. Frederick W. Telling stepped down as Chairman but remains an independent director.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future performance, or specific risk factors beyond the cessation of the ATM Program. The termination of the ATM Program indicates a strategic decision to stop raising capital through this specific mechanism at this time.
Key Facts for Investor Verification
- Confirm the effective date of the ATM Program termination (December 29, 2022) and its impact on future capital raising capabilities.
- Verify the new leadership structure with Charles Pope as Chairman and the continued role of Dr. Frederick W. Telling.
- Review the total capital raised in Q4 2022 via the ATM Program (approximately $72,345 based on disclosed share count and average price).
- Check subsequent filings for any new financing arrangements to replace the terminated ATM Program.